Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

BRCA-PREVENT

Financiado

Building consensus for a new approach to breast cancer prevention in women with...

Building consensus for a new approach to breast cancer prevention in women with a BRCA1 mutation Women with germline mutations in the BRCA1 genes face a 40-fold increased risk of developing breast and ovarian cancer. As a result, and due to a lack of other options, many women with a BRCA1 mutation choose to undergo drastic ri... ver más

28/02/2025

UIBK

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITAET INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 1 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-08-03

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

UIBK

150.00K€ | Lider

Proyectos interesantes

PDC2021-121735-I00 BREAST CANCER PREVENTION BY ENHANCING POSTLACTATIONAL INVOLU... 133K€ Cerrado

SAF2014-57680-R PROFUNDIZANDO EN EL MECANISMO DE ACCION DE LOS INHIBIDORES D... 97K€ Cerrado

SAF2017-88854-R ESTRATEGIAS FARMACOLOGICAS DE PREVENCION DEL CANCER DE MAMA... 169K€ Cerrado

CNS2023-145149 Cáncer 200K€ Cerrado

SAF2010-20493 IMPLICACIONES DEL TIPO DE MUTACION GERMINAL EN EL PRONOSTICO... 97K€ Cerrado

PID2020-118527RB-I00 EVALUACION DE LA PREVENCION DEL CANCER DE MAMA MEDIANTE ANAL... 206K€ Cerrado

Últimas noticias

25-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 52 concesiones

25-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 1 concesiones

25-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 6 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2023-08-03
Fecha Fin: 2025-02-28

Líder del proyecto

UNIVERSITAET INNSBRUCK

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Women with germline mutations in the BRCA1 genes face a 40-fold increased risk of developing breast and ovarian cancer. As a result, and due to a lack of other options, many women with a BRCA1 mutation choose to undergo drastic risk reducing surgery (removal of both breasts, ovaries and Fallopian Tubes) when they are still very young. Drugs currently recommended for prevention of breast cancer, such as tamoxifen or aromatase inhibitors, do not prevent those cancers with the poorest prognosis, such as triple negative breast cancer. Methods to prevent breast and ovarian cancers in these women are therefore a critical unmet medical need. We and others have identified progesterone as one of the key drivers for triple negative breast cancer development. We have shown that progesterone is consistently elevated during the luteal phase of the menstrual cycle in BRCA1 mutation carriers compared to women without such a mutation, and preliminary data point to progesterone receptor antagonists, such as mifepristone, as a promising class of drugs for primary prevention. Clinical trials of primary cancer prevention are extremely challenging due to the time-gap between the start of the cancer-preventive treatment and the primary endpoints (i.e., cancer incidence and cancer death). Current tools do not predict the likelihood of future cancer development with sufficient accuracy to be used to determine the preventive efficacy of a new treatment. We have developed DNA methylation markers reflecting tissue age and cell type that are increased in cancer tissue as well as in normal tissue from women with a BRCA1 mutation and could be used to monitor preventive efficacy. Clinical trials are now required to further investigate the use of antiprogestins for the prevention of breast and ovarian cancer. This ERC Proof of Concept grant aims to bring consensus among the scientific, patient and regulatory/ethical communities regarding the design and conduct of an initial clinical trial.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores